Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

This study has suspended participant recruitment.
(drug potency expiration and Ascenta's inability to manufacture more drug)
Sponsor:
Information provided by (Responsible Party):
Francis (Frank) Worden, University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT01633541
First received: June 29, 2012
Last updated: June 21, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: January 2015
  Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)